You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020224026
Dec 202074018
Jan 20214607
Feb 202184011
Mar 2021142017
Apr 2021110013
May 202126013
Jun 20210014
Jul 20210020
Aug 20210017
Sep 20210011
Oct 202164033
Nov 2021111024
Dec 202194014
Jan 2022262016
Feb 202292016
Mar 202268026
Apr 2022150020
May 2022144022
Jun 2022134010
Jul 2022180021
Aug 2022178025
Sep 202290011
Oct 2022252020
Nov 2022214018
Dec 2022126017
Jan 2023140012
Feb 2023140026
Mar 2023116018
Apr 2023110018
May 2023116016
Jun 2023132010
Jul 202372013
Aug 202398012
Sep 20237808
Oct 20235407
Nov 202346013
Dec 20237409
Jan 20243807
Feb 20245004
Mar 20245405
Apr 20249208
May 202451012
Jun 20245607
Jul 20246004
Aug 202438011
Sep 202474012
Total45540692